PRAME and metastatic melanoma: In fact, in one of the first studies conducted on this topic, the authors [25] presented their findings regarding the immunoexpression of PRAME in 400 melanocytic tumors, including 155 primary and 100 metastatic melanomas, and 145 melanocytic nevi.